Related by context. All words. (Click for frequent words.) 77 EGFR mutations 77 K ras mutations 73 KRAS mutation 72 EGFR mutation 72 ABCB1 71 TOP2A 71 mutated K ras 70 K ras 70 KRAS status 69 T#I [002] 69 activating mutations 69 KRAS gene 69 hypermethylated 69 pancreatic adenocarcinoma 69 MLH1 69 HER2 expression 68 BRAF mutations 68 breast carcinoma 68 missense mutations 68 HER2 receptor 68 BRAF mutation 68 poor metabolizers 68 rs# [004] 68 advanced adenomas 68 mCRC patients 68 GSTM1 68 mutated KRAS 68 BRCA2 mutation carriers 68 FLT3 67 CDKN2A 67 HER2 overexpression 67 p# biomarker 67 TGFBR1 * 6A 67 CYP#C# [001] 67 NSCLC tumors 67 LRAT 67 PTPN# 67 promoter methylation 67 FGFR2 67 prostate carcinoma 67 KRAS mutant 67 colorectal carcinomas 67 CYP#C# [002] 67 hepatocellular carcinomas 67 tumor histology 67 VKORC1 67 nonmetastatic 67 lymph node metastases 67 Hurthle cell 67 EGFR gene 67 p# mutation 66 CC genotype 66 ERCC1 66 pCR 66 distant metastasis 66 normal karyotype 66 histologies 66 UGT#A# * 66 estrogen receptor ER 66 BRCA1 mutations 66 BRCA2 carriers 66 MSH2 66 HER2 negative 66 EpCAM 66 histological subtype 66 HER2 amplification 66 B7 H3 66 EGFR inhibitors 66 chemoresistant 66 BRAF V#E mutation 66 EGFR HER2 66 xenograft models 66 differentially expressed genes 66 relapsed SCLC 66 gefitinib Iressa 66 HBsAg 66 seropositivity 66 causal variants 66 K ras mutation 66 GSTT1 66 APOE e4 66 Her2/neu 66 Leukemias 65 AGTR1 65 cisplatin resistant 65 prostate cancer CaP 65 EGFR tyrosine kinase inhibitors 65 lymph node metastasis 65 GISTs 65 c MYC 65 TIMP 1 65 adenocarcinomas 65 Epidermal Growth Factor Receptor 65 V#F mutation 65 mutated KRAS gene 65 cancer mCRC 65 RRM1 65 HER2 positive cancers 65 TP# mutations 65 advanced adenoma 65 gemcitabine carboplatin 65 underwent resection 65 FLT3 ITD 65 poorer prognosis 65 NPM1 mutations 65 breast cancer subtypes 65 Squamous 65 rs# [002] 65 hormone receptor negative 65 SPINK1 65 GSTP1 65 p# activation 65 GBM tumors 65 K ras gene 65 colorectal carcinoma 65 TT genotype 65 EGFR protein 65 cyclin E 65 HGPIN 65 elevated LDH 65 MTHFR 65 HER2 positive metastatic breast 65 KRAS wild 65 PITX2 65 PIK3CA 65 endocrine therapies 65 somatic mutations 65 ovarian carcinoma 65 EGFR expression 65 EGFR mutant 65 ErbB2 positive 65 ERBB2 65 CYP#D# genotype 65 Recurrence Score 65 PNH patients 65 fluvastatin 65 LRP5 65 breast carcinomas 65 BRCA mutations 65 sarcomatoid 65 MGUS 65 KIT mutations 65 Vidaza ® 65 IL#B 65 K RAS 65 Folfox 65 BRCA mutation 65 prognostic markers 65 prostate adenocarcinoma 65 MGd 65 cMET 65 biochemical relapse 65 HBeAg negative 64 Doxil ® 64 tumor subtypes 64 trastuzumab Herceptin ® 64 cytogenic 64 nonsmall cell lung cancer 64 papillary renal cell carcinoma 64 recurrent NSCLC 64 Genotypes 64 hepatoma 64 TTR gene 64 deletion 5q 64 pDCs 64 genetic polymorphisms 64 epithelial tumors 64 C#Y 64 methylation patterns 64 BRCA2 mutation 64 IFN α 64 WT1 64 myeloproliferative disorders 64 malignant lesions 64 MAGE A3 64 biochemical recurrence 64 constitutively expressed 64 atypical hyperplasia 64 TRAIL induced apoptosis 64 non mutated KRAS 64 squamous histology 64 EGFRvIII 64 HepG2 cells 64 CIN2 + 64 methylation markers 64 renal cell carcinomas 64 CDH1 64 BRCA1 mutation carriers 64 lactate dehydrogenase LDH 64 PCa 64 genotypic resistance 64 bladder carcinoma 64 antiangiogenic therapy 64 HBeAg 64 Clusterin 64 rs# [001] 64 immunoreactivity 64 stage IIIb IV 64 KRAS oncogene 64 HER3 64 KRAS 64 mTOR inhibitors 64 TMPRSS2 ERG 64 imatinib Gleevec 64 molecular subtypes 64 haematopoietic 64 serous ovarian cancer 64 relapsed MM 64 nodal metastasis 64 HLA DR 64 M#V mutation 64 estrogen receptor negative 64 vimentin 64 FLT3 mutations 64 Leydig cell 64 completely resected 64 immunohistochemical analysis 64 MAGE A3 ASCI 64 BRCA2 mutations 64 germline mutations 64 CR nPR 64 Wwox 64 PARP inhibition 64 VIPR2 64 alkylating agents 64 cTnI 64 heterozygotes 64 carcinoembryonic antigen 64 metastatic neuroendocrine tumors 64 paclitaxel cisplatin 64 alkaline phosphatase ALP 64 eIF 4E 64 erlotinib Tarceva ® 64 NNRTI resistance 64 azacytidine 64 BRAF V#E 64 underwent surgical resection 64 hypereosinophilic syndrome 64 coinfected patients 64 precursor lesions 64 androgen receptor AR 64 Factor Receptor 64 flavopiridol 64 basal cell nevus syndrome 64 herpesviruses 64 pT3 64 NF kB pathway 64 HIV HCV coinfected 64 benign moles 64 contralateral breast 63 EGFR mutation status 63 situ LCIS 63 lymphoid malignancies 63 baseline HbA1c 63 baseline LDH 63 gene polymorphisms 63 metastatic prostate 63 HCV genotype 63 taxane therapy 63 IgA deficiency 63 EGFr 63 mRNA expression 63 histologic subtypes 63 ZNF# 63 progesterone receptor negative 63 seronegative 63 micrometastases 63 endometrial cancers 63 BRCA1 BRCA2 63 CYP#D# 63 Li Fraumeni 63 NKX#.# 63 antiproliferative effects 63 adriamycin 63 CCR5 delta# 63 mutant allele 63 oblimersen 63 syngeneic 63 EGFR mutation positive 63 seminomas 63 operable breast cancer 63 immunohistochemical staining 63 variant allele 63 galiximab 63 BRCA2 gene mutation 63 antibody titer 63 Immunohistochemical analysis 63 CD# expression [002] 63 specific antigen PSA 63 HER2 positive tumors 63 prognostic biomarker 63 EGFR activating mutations 63 HGS ETR1 63 standard chemotherapy regimens 63 BCR ABL mutations 63 MAGE A3 protein 63 NMIBC 63 hormone receptor status 63 PROSTVAC VF 63 HAAH 63 mucinous 63 progesterone receptor PR 63 recurrent glioblastoma multiforme 63 microdeletions 63 lung adenocarcinomas 63 DNA methylation patterns 63 gefitinib 63 invasive carcinomas 63 Gleevec resistant 63 chronic eosinophilic leukemia 63 FOLFIRI 63 tyrosine phosphorylation 63 myeloproliferative diseases 63 CD# + [001] 63 HbF 63 mapatumumab 63 HLA DRB1 * 63 small lymphocytic lymphoma 63 gemcitabine Gemzar 63 neoplastic 63 p#INK#a 63 p# mutations 63 IGF IR 63 thyrotropin levels 63 multivariate analyzes 63 KRAS mutations occur 63 locoregional recurrence 63 imatinib resistant 63 platelet reactivity 63 decitabine 63 mutated BRCA1 63 XELOX 63 activating mutation 63 Estrogen Receptor 63 lymphocyte count 63 hypermethylation 63 BMPR2 63 APOE ε4 63 microsatellite instability 63 mycophenolate mofetil 63 HER2 neu 63 MYCN amplification 63 5 HTTLPR 63 PSADT 63 follicular lymphomas 63 squamous cell lung cancer 63 miR #a [001] 63 LRP6 63 gastric adenocarcinoma 63 TNF blocker therapy 63 prognostic marker 63 clinicopathological features 63 ASCUS 63 lymphocytosis 63 HER2/neu 63 Kaplan Meier analysis 63 genes CYP#C# 63 splice variants 63 distant metastases 63 RASSF1A 63 breast cancer genes BRCA1 63 thyroid carcinoma 63 familial ALS 63 mutated p# 63 pegylated liposomal doxorubicin 63 APOPTONE 63 narcolepsy cataplexy 63 mutant p# 63 chemosensitivity 63 EUS FNA 63 cTnT 63 APTIVUS r 63 axillary lymph nodes 63 CCR9 63 ERalpha 63 CLL cells 63 miRNA expression 63 FOLFOX4 63 virulence genes 63 urothelial carcinoma 63 colorectal neoplasia 63 lymph node involvement 63 heterozygous 63 histological subtypes 63 HGS ETR2 63 ovarian endometrial 63 genotypic 63 liver metastasis 63 homozygotes 62 advanced neoplasia 62 castrate resistant 62 HLA DR2 62 ADPKD 62 lymphocyte counts 62 sCJD 62 invasive lobular 62 genetic loci 62 invasive ductal 62 axillary nodes 62 K#R [002] 62 CD#c 62 Cytotoxic T 62 CYP#A# [002] 62 troponin T 62 Antitumor Activity 62 dizygotic twins 62 pharmacodynamic parameters 62 PTEN mutations 62 coinfected 62 MAPK pathway 62 HBx 62 PTEN gene 62 metastatic castration resistant 62 HNSCC 62 TNFR1 62 Ki# 62 pT2 62 refractory chronic lymphocytic 62 estrogen receptor progesterone receptor 62 IKZF1 62 dasatinib 62 Stat5 62 KIF6 carriers 62 metastatic lesions 62 SHANK3 62 c KIT 62 medically inoperable 62 F FDG PET 62 urine cytology 62 Ph + acute lymphoblastic 62 Cytogenetic 62 CanAg 62 abnormal cytology 62 lymphoid cells 62 SLC#A# [002] 62 CCR7 62 tumorigenicity 62 cell adhesion molecule 62 trastuzumab Herceptin R 62 demonstrated antitumor activity 62 novel VDA molecule 62 murine models 62 CsA 62 paricalcitol 62 MGMT gene 62 Xelox 62 miRview ™ squamous 62 log# copies mL 62 recurrent VTE 62 MDR1 62 Diffuse Large B 62 CD4 + CD# 62 T#I mutation 62 preoperative chemotherapy 62 TEAEs 62 CYT# potent vascular disrupting 62 virologic responses 62 thyroglobulin 62 p# biomarkers 62 TYMS 62 anti JCV antibodies 62 susceptibility loci 62 histologically 62 hypomethylation 62 pancreatic neuroendocrine tumors 62 serum creatinine levels 62 gene rearrangements 62 nonmelanoma skin cancers 62 telomere lengths 62 ApoE4 62 heavily pretreated 62 p# Shc 62 NPM1 62 #.#ng/ml 62 EGF receptors 62 apolipoprotein E4 62 thalidomide Thalomid 62 thyrotropin 62 prognostic factors 62 histologic subtype 62 hematopoietic cancers 62 T1c 62 hTERT 62 antiangiogenic activity 62 JAK2 V#F 62 neoadjuvant chemotherapy 62 pg ml 62 neoplastic cells 62 gastrointestinal stromal tumors GISTs 62 #q#.# [001] 62 retinoic acid receptor 62 cytokeratin 62 HER2 positivity 62 NRTI resistance 62 polymorphisms 62 Pharmacokinetics PK 62 TIMP 62 HLA DQ2 62 IGF 1R 62 chromosomal rearrangement 62 chromosomal aberrations 62 myelodysplastic myeloproliferative diseases 62 ERK1 2 62 univariate analysis 62 FDG PET 62 node metastases 62 metastatic renal cell carcinoma 62 metaplasia 62 GIST tumors 62 NFKBIA 62 ERK signaling 62 Jhdm2a 62 hematological parameters 62 genomic alterations 62 anaplastic lymphoma kinase 62 EphA2 62 PKCi 62 obstructive coronary artery 62 mutational status 62 pheochromocytoma 62 GPC5 62 adjuvant chemotherapy 62 JAK2 62 gene amplification 62 carcinoid 62 K#N 62 resected pancreatic cancer 62 pretransplant 62 androgen independent 62 ritonavir boosted 62 unresectable tumors 62 plasma folate 62 trans retinoic acid 62 #q# [002] 62 locoregional 62 KIF6 gene 62 azacitidine 62 bevacizumab Avastin ® 62 androgen deprivation 62 cardiac troponin T 62 #p#.# [002] 62 effector function 62 MYH9 gene 62 myelofibrosis polycythemia vera 61 sorafenib Nexavar 61 trabectedin 61 DLC1 61 S#A# [002] 61 invasive carcinoma 61 caveolin 1 61 #p# [001] 61 GPNMB 61 familial pancreatic cancer 61 CDK4 61 EGFR TKIs 61 c MET 61 constitutively active 61 selective modulator 61 inherited mutations 61 inhibin B 61 5q deletion 61 noncarriers 61 ependymomas 61 flutamide 61 TSC1 61 System IPSS 61 neuroblastoma tumors 61 mosaicism 61 metastatic RCC 61 HES CEL 61 UGT#A# 61 nonnucleoside reverse transcriptase inhibitors 61 neoadjuvant 61 Foxp3 61 undetectable HBV DNA 61 HLA DR4 61 low dose cytarabine 61 gene locus 61 PDGFR 61 TPMT 61 CYP#C# * 61 immunocompetent 61 Subgroup analyzes 61 Adjuvant chemotherapy 61 clusterin 61 ApoE4 gene 61 SNP rs# [001] 61 Heterozygous 61 mutant alleles 61 peripheral blood mononuclear 61 chronic myeloid 61 KRAS gene mutations 61 clinically localized prostate 61 protein encoded 61 CIMZIA ™ 61 anti EGFR antibody 61 thyroid peroxidase 61 seliciclib 61 FGFR2 gene 61 ABCB1 gene 61 rs# [003] 61 tipranavir ritonavir 61 inactivating mutations 61 FUS1 61 PDGFRA 61 HSCT 61 CMV disease 61 anti HBs 61 SNP rs# [002] 61 heterozygote 61 mutated BRAF gene 61 pulmonary metastases 61 severe neutropenia 61 allele frequencies 61 antiangiogenic agents 61 metastatic malignant 61 HER-2/neu 61 MET amplification 61 hENT1 61 HCV genotypes 61 BARACLUDE ® 61 stage IIIB IV 61 Cathepsin B 61 serum concentrations 61 immunodeficient 61 IDH1 mutation 61 predictive biomarker 61 lung adenocarcinoma 61 systemic ALCL 61 gastrointestinal stromal tumors 61 immunohistochemical 61 tyrosine kinase inhibitors 61 complete cytogenetic response 61 E#F# 61 Akt activation 61 ApoE 61 chronic HBV 61 abnormal p# biomarker 61 Stage IIIb 61 Granulocyte Colony Stimulating Factor 61 IgG antibody 61 FGFR1 61 anaplastic lymphoma kinase ALK 61 hamartomas 61 prognostic significance 61 Cystatin C 61 PALB2 61 heparanase 61 invasive lobular carcinoma 61 splice junctions 61 NSCLC 61 Angiotensin converting enzyme 61 DMARDS 61 salpingo oophorectomy 61 SMAD4 61 paragangliomas 61 IFN gamma 61 tumor antigen 61 vitro assay 61 chromosome #p# [002] 61 radiochemotherapy 61 Anthracycline 61 metastatic GIST 61 HBeAg positive 61 non squamous NSCLC 61 mesothelin 61 leukocyte count 61 estrogen receptor alpha 61 genes BRCA1 61 gene polymorphism 61 M#V 61 APOE genotype 61 N cadherin 61 GBA mutations 61 HPV subtypes 61 EGFR TKI 61 BRAF gene mutations 61 multivariate Cox 61 IGFBP 3 61 ELISpot 61 erlotinib Tarceva 61 monocytic 61 JAK3 61 clinicopathologic 61 constitutively activated 61 immunized mice 61 molecular biomarkers 61 LHRH receptor positive 61 hsCRP levels 61 #q# [001] 61 microRNA expression 61 GnRH agonists 61 mRCC 61 chromosome #q# [001] 61 APOL1 61 TRAIL R1 61 Thal Dex 61 TLR9 agonists 61 N. gonorrhoeae 61 HIF 1α 61 fulvestrant 61 serum albumin 61 mg kg dose 61 breast endometrial 61 untreated metastatic melanoma 61 TLR3 61 Flu Cy 61 cerebral microbleeds 61 Lenalidomide 61 anastrazole 61 eotaxin 61 MDM2 61 pomalidomide 61 myeloproliferative 61 μmol L 61 trastuzumab 61 tumor xenograft models 61 imatinib Gleevec ® 61 Her2 61 colorectal polyp 61 receptor tyrosine kinase inhibitor 61 sporadic ALS 61 mutant KRAS 61 metastatic gastric 61 apolipoprotein E gene 61 adjuvant tamoxifen 61 serum biomarkers 61 pancreatic carcinoma 61 refractory metastatic 61 glial tumors 61 EGFR inhibition 61 adenomatous polyps 61 PBMCs 61 immunomodulation 61 lobular carcinoma 61 CTAP# Capsules 61 standard chemotherapy regimen 61 stage IIIB 61 CYP#C# genotype 61 Bcl XL 61 neuropilin 61 tumor necrosis 61 Genetic variants 61 RAR beta 61 #p# [003] 61 clade B 61 progesterone receptors 61 Azacitidine 61 enzastaurin 61 angiographic outcomes 61 malignant ovarian 61 RECIST Response Evaluation Criteria 61 p#HER# 61 endometrial hyperplasia 61 imatinib resistance 61 MLL2 61 lobular carcinomas 61 EGFR receptor 61 clonogenic 61 cetuximab 61 #q# deletion 61 JAK2 enzyme 61 chronic HBV infection 61 IDH mutations 61 histone deacetylases 61 PC# cells 61 pancreatic lung 61 tumor subtype 61 inflammatory biomarkers 61 renal carcinoma 61 prognostic indicator 61 proto oncogene 61 DQB1 * 61 anthracycline containing 61 estrogen receptors 61 BRCA1 mutation 61 gp# vaccine 61 Platinol ® cisplatin 61 castrate resistant prostate cancer 61 survivin 61 TRAIL R2 61 sipuleucel T 61 biopsied breast 61 Papillary 61 HLA genes 61 bicalutamide 61 p# MAPK 61 melphalan prednisone 61 granulocyte 60 Pegylated Interferon 60 MetMAb 60 orally administered inhibitor 60 bronchoalveolar lavage fluid 60 immunostaining 60 transferrin saturation 60 Interferon Beta 60 pituitary adenomas 60 ipsilateral breast 60 EpCAM expression 60 chlorambucil 60 Cholangiocarcinoma 60 epithelial ovarian cancer 60 Subgroup analysis 60 CYP#D# gene 60 achieved CCyR 60 prospectively defined 60 PCA3 gene 60 NPM1 mutation 60 potent inhibition 60 tumor biopsies 60 multivariable analysis 60 heavily pretreated patients 60 neoplasias 60 gene expression profiles 60 5-fluorouracil/leucovorin 60 intracranial hemorrhage ICH 60 SOD1 gene 60 GNAQ 60 RAF kinase VEGFR 60 6 mercaptopurine 60 imetelstat 60 HuLuc# 60 liver metastases 60 HCV replicon 60 PDE#A 60 OGG1 60 orthologs 60 del 5q MDS 60 CDK8 60 extramedullary 60 malignant nodules 60 octreotide LAR 60 histologic 60 cisplatin chemotherapy 60 cathepsins 60 IDH2 60 KRAS mutant tumors 60 aminotransferase levels 60 isotypes 60 CD# expression [001] 60 prostate cancer CRPC 60 castration resistant 60 xenograft tumors 60 NKG2D 60 interferon gamma 1b 60 response pCR 60 antiestrogen 60 NAbs 60 FDG-PET/CT 60 TRAF1 C5 60 APOE4 60 hepatic metastases 60 monozygotic twins 60 liver transplant recipients 60 hA# 60 osteopontin 60 whose tumors overexpress 60 KRAS BRAF 60 carcinoid tumors 60 HIF 1alpha 60 ERBB4 60 Mutational 60 PXD# 60 adjuvant radiation 60 malignant prostate 60 Chronic Lymphocytic Leukemia CLL 60 microdeletion 60 interferon IFN 60 clodronate 60 preoperative PSA 60 ductal carcinomas 60 TNFalpha 60 sarcosine 60 transthyretin amyloidosis 60 ENMD # 60 BCL#A 60 Polymorphisms 60 subependymal giant cell 60 HER2 gene 60 pharmacokinetic interactions 60 nelfinavir 60 #q#.# [002] 60 monoinfected patients 60 BARD1 60 BCIRG 60 Naive Patients 60 FGFR3 60 alpha synuclein gene 60 HBeAg seroconversion 60 EGFR 60 ALDH 60 dacarbazine chemotherapy 60 TAp# 60 squamous 60 gene loci 60 thrombophilia 60 intact parathyroid hormone 60 adverse cytogenetics 60 SOX9 60 5 FU leucovorin 60 elacytarabine 60 CCL#L# 60 chemokine receptor 60 bcl 2 60 HCV SPRINT 60 breast pancreatic 60 clinico pathological 60 virologic failure 60 posaconazole 60 CTNNB1 60 transgene expression 60 infliximab monotherapy 60 docetaxel chemotherapy 60 IGFBP 60 metastatic pancreatic 60 colon carcinoma 60 tanespimycin 60 isotype 60 affective psychosis 60 pan HDAC inhibitor 60 poly ADP ribose polymerase 60 letrozole Femara 60 ALND 60 contralateral breast cancer 60 nonischemic 60 Fas ligand 60 chromosomal regions 60 cytogenetic abnormalities 60 Epidemiologic studies 60 taxane chemotherapy 60 cranial irradiation 60 malignant pleural mesothelioma 60 lung ovary 60 atypical ductal hyperplasia 60 relapsed ALL 60 TACI mutations 60 FOLFOX 60 unresectable stage 60 microglial activation 60 tryptase 60 OnDose TM 60 osteosarcomas 60 Leydig cells 60 oral FTY# 60 apolipoprotein E 60 estrogen receptor positive 60 replicon 60 serologic 60 circulating endothelial cells 60 HBeAg positive patients 60 monocyte chemoattractant protein 60 COX2 60 beta1 integrin 60 ZOLINZA 60 TP# gene 60 Apolipoprotein E4 60 IL #R 60 nodal metastases 60 hepatocellular carcinoma HCC 60 antiandrogens 60 AML MDS 60 glioma tumors 60 homodimers 60 BEXXAR Therapeutic Regimen 60 sulphonylureas 60 vincristine doxorubicin 60 Hormone Refractory Prostate Cancer 60 Atypical Hemolytic Uremic Syndrome 60 CSF biomarkers 60 pro angiogenic 60 FOLFOX chemotherapy 60 Endometrial 60 VEGF expression 60 lymphovascular invasion 60 IgG antibodies 60 extracolonic 60 bortezomib 60 beta carotene supplementation 60 circadian genes 60 cilengitide 60 TNF α 60 sequence homology 60 BRAF V# mutation 60 Cutaneous T 60 differentially expressed proteins 60 lung metastases 60 ALK inhibitor 60 oral squamous cell 60 TCF#L# 60 CagA 60 dasatinib Sprycel ® 60 HG PIN 60 adalimumab Humira 60 abacavir Ziagen 60 GABRA2 60 alvespimycin 60 allogeneic stem cell 60 metastatic renal cell 60 serum antibodies